LAMY Aude

Dr. LAMY Aude


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2011 in Laboratory Investigation
Verified
Journal Article
Closed access
LALAMY Aude
LAMY Aude
FBFrance Blanchard
France Blanchard
FPFlorence Le Pessot
Florence Le Pessot
RSRichard Sesboüé
Richard Sesboüé
FFFrédéric Di Fiore
Frédéric Di Fiore
JSJean-Christophe Sabourin
Jean-Christophe Sabourin

4 March 2013 in BMC Medicine
Verified
Journal Article
Open access
PDF file
GBGemma Bruera
Gemma Bruera
KCKatia Cannita
Katia Cannita
DGDaniela Di Giacomo
Daniela Di Giacomo
LALAMY Aude
LAMY Aude
TFThierry Frébourg
Thierry Frébourg
EREnrico Ricevuto
Enrico Ricevuto
Background: Prognosis of KRAS wild-type and mutant metastatic colorectal cancer (MCRC) patients (pts) treated with bevacizumab (BEV)-containing chemotherapy is not significantly different. Since specific KRAS mutations confer different aggressive behaviors, the prognostic role of prevalent KRAS mutations was retrospectively evaluated in MCRC pts treated with first line FIr-B/FOx, associating BEV to triplet chemotherapy. Methods: Tumor samples were screened for KRAS codon 12, 13 and BRAF V600E mutations by SNaPshot and/or direct sequencing. MCRC pts A, 15 (25.4%); c.35 G > T, 7 (11.8%); c.38 G > A, 3 (5%); other, 3 (5%). KRAS wild-type, 31 pts (52.7%). The objective response rate (ORR), PFS and OS were, respectively: c.35 G > A mutant, 71%, 9 months, 14 months; other than c.35 G > A mutants, 61%, 12 months, 39 months. OS was significantly worse in c.35 G > A pts compared to KRAS wild-type (P = 0.002), KRAS/BRAF wild-type (P = 0.03), other MCRC patients (P = 0.002), other than c.35 G > A (P = 0.05), other codon 12 (P = 0.03) mutant pts. OS was not significantly different compared to c.35 G > T KRAS mutant (P = 0.142). Conclusions: KRAS c.35 G > A mutant status may be significantly associated with a worse prognosis of MCRC pts treated with first line FIr-B/FOx intensive regimen compared to KRAS/BRAF wild type and other than c.35 G > A mutant pts.

8 November 2012 in BMC Medicine
Verified
Journal Article
Open access
PDF file
GBGemma Bruera
Gemma Bruera
KCKatia Cannita
Katia Cannita
DGDaniela Di Giacomo
Daniela Di Giacomo
LALAMY Aude
LAMY Aude
Giancarlo TronconeGiancarlo Troncone
Giancarlo Troncone
EREnrico Ricevuto
Enrico Ricevuto
Bevacizumab (BEV) plus triplet chemotherapy can increase efficacy of first-line treatment of metastatic colorectal cancer (MCRC), particularly integrated with secondary liver surgery in liver-limited (L-L) patients. The prognostic value of the KRAS genotype in L-L and other or multiple metastatic (O/MM) MCRC patients treated with the FIr-B/FOx regimen was retrospectively evaluated.

17 February 2022 in Cancers
Verified
Journal Article
Open access
PDF file
Radu PirlogRadu Pirlog
Radu Pirlog
NPNicolas Piton
Nicolas Piton
LALAMY Aude
LAMY Aude
FGFLORIAN GUISIER
FLORIAN GUISIER
Ioana Berindan-NeagoeIoana Berindan-Neagoe
Ioana Berindan-Neagoe
FMFlorent MARGUET
Florent MARGUET
Lung adenocarcinoma (LUAD) is the major subtype of non-small cell lung cancer, accounting for approximately 60% of cases. Molecular analysis of LUADs showed that the KRAS gene is mutated in up to 30% of cases; such cases were previously considered “undruggable”. The KRAS G12C mutation has become a hot topic of research after initial, promising, phase I and II trials with targeted inhibitors. We analyzed the morphological and genomic landscape of 202 KRAS G12C mutated LUADs using next-generation sequencing, and identified a specific subtype of patients that could show an improved response to KRAS G12C inhibitors. The main histological subtype was acinar in 29.7% of cases. Tumor-infiltrating lymphocytes (TILs) were highly or moderately abundant in more than 60% of cases. The immunohistochemical profile showed TTF1 positivity in 78.7% of cases and PD-L1 positivity in 44.1% of cases. The molecular profile showed an association between KRAS G12C and STK11 mutations in 25.2% of cases. This subgroup was associated with a statistically significant lower TTF1 (p = 0.0092) and PD-L1 (p < 0.0001) positivity. This type of combined morphological and molecular analysis can improve our understanding of tumor biology, and help us to identify specific patient subgroups that can achieve the best treatment response.

11 October 2013 in BMC Cancer
Verified
Journal Article
Open access
PDF file
TGthe BRAF EQA Group
the BRAF EQA Group
JEJean-François Emile
Jean-François Emile
JTJulie Tisserand
Julie Tisserand
LBLoic Bergougnoux
Loic Bergougnoux
FNFrédérique Nowak
Frédérique Nowak
PLPierre Laurent-Puig
Pierre Laurent-Puig
Knowledge about tumour gene mutation status is essential for the treatment of increasing numbers of cancer patients, and testing quality has a major impact on treatment response and cost. In 2012, 4,629 tests for BRAF p.V600 were performed in France, in patients with melanomas. Two batches of unstained melanoma sections were sent, in May and November 2012, to the 46 laboratories supported by the French National Institute of Cancer (INCa). An external quality assessment (EQA) evaluated mutation status, response times and compliance with INCa recommendations. All the French laboratories involved in testing participated in the EQA. Fourteen different methods were used to detect BRAF mutations, most consisting of combinations of in-house techniques. False responses were noted in 25/520 cases (4.8%), 11 of which concerned confusion between p.V600E and p.V600K. Thus, 2.7% of responses would have led to inappropriate treatment. Within six months, mean response times decreased from 22 to 12 days (P<0.001), and the percentage of samples evaluated by a pathologist for tumour cell content increased, from 75.2% to 96.9% (P<0.001). Despite the use of non-certified methods, the false response rate was low. Nationwide EQA can improve the quality of molecular pathology tests on tumours.

8 April 2013 in BMC Cancer
Verified
Journal Article
Open access
PDF file
NSNasrin Sarafan-Vasseur
Nasrin Sarafan-Vasseur
DSDavid Sefrioui
David Sefrioui
DTDavid Tougeron
David Tougeron
LALAMY Aude
LAMY Aude
FBFrance Blanchard
France Blanchard
RSRichard Sesboüé
Richard Sesboüé
The EGFR 3′ untranslated region (UTR) harbors a polyadenine repeat which is polymorphic (A13/A14) and undergoes somatic deletions in microsatellite instability (MSI) colorectal cancer (CRC). These mutations could be oncogenic in colorectal tissue since they were shown to result into increased EGFR mRNA stability in CRC cell lines.